

09/980039

REC'D U 3 MAR 2000

WIPO PCT

EJA

P1 208623

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

**UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office**

February 29, 2000

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE UNDER 35 USC 111.**

**APPLICATION NUMBER: 60/111,913
FILING DATE: December 11, 1998
PCT APPLICATION NUMBER: PCT/US99/28972**



**By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS**

H. L. Jackson
**H. L. JACKSON
Certifying Officer**

**PRIORITY
DOCUMENT**

**SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)**

PROVISIONAL APPLICATION FOR PATENT COVER SHEET
This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(b)(2).

Docket Number		U 012030-5		Type a plus sign (+) inside this box →		+	
INVENTOR(s)/APPLICANT(s)							
LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)				
DAVIS	BONNIE		160 COLD SPRING ROAD SYOSSET, NEW YORK 11791				
TITLE OF THE INVENTION (280 characters max)							
USE OF ACETYLCHOLINESTERASE INHIBITORS ON THE MODULATION OF THE HYPOTHALAMIC-PITUITARY AXIS							
CORRESPONDENCE ADDRESS							
LADAS & PARRY 26 WEST 61ST STREET NEW YORK, NEW YORK 10023							
STATE	NEW YORK	ZIP CODE	10023	COUNTRY	U.S.A.		
ENCLOSED APPLICATION PARTS (check all that apply)							
<input checked="" type="checkbox"/> Specification	Number of pages	6	<input type="checkbox"/> Small Entity Statement				
<input type="checkbox"/> Drawing(s)	Number of Sheets		<input type="checkbox"/> Other (specify)				
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)							
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees				FILING FEE AMOUNT(S)	\$ 150.00		
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees and credit deposit Account Number.	12-0425						

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

- ☒ No.
☐ Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

SIGNATURE

TYPED OR PRINTED NAME

JANET I. CORD

Date

12 / 11 / 1998

REGISTRATION NO.
(if appropriate)

33,778

☐ Additional inventors are being named on separately numbered sheets attached hereto

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

Burden Hour Statement. This form is estimated to take 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, DC 20231.

14 64 05 3.807.09US

A/PROV



Attorney's Docket No.: U 012030-5

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: BONNIE DAVIS

For: USE OF ACETYLCHOLINESTERASE INHIBITORS ON THE MODULATION OF
THE HYPOTHALAMIC-PITUITARY-GONADAL AXIS

Assistant Commissioner for Patents
Washington, D.C. 20231

EXPRESS MAIL CERTIFICATE

"Express Mail" Label Number EJ405380709US

Date of Deposit DECEMBER 11, 1998

I hereby certify that the following attached paper or fee

ACKNOWLEDGMENT POSTCARD
PROVISIONAL APPLICATION FOR PATENT COVER SHEET
TRANSMITTAL
6 PAGES OF SPECIFICATION
\$150.00 (FILING FEE) (CHECK ENCLOSED)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

BEATRIZ PEREIRA

(Typed or print name of person mailing paper of fee)

Beatriz Pereira

(Signature of person mailing paper of fee)

Note: Each paper must have its own certificate and the "Express Mail" label number as a part thereof or attached thereto. When, as here, the certification is presented on a separate sheet, that sheet must (1) be signed and (2) fully identified and be securely attached to the paper or fee it accompanies. Identification should include the serial number and filing date of the application as well as the type of paper being filed, e.g. complete application, specification and drawings, responses to rejection or refusal, notice of appeal, etc. If the serial number of the application is not known, the identification should include at least the name of the inventor(s) and the title of the invention

Note: The label number need not be placed on each page. It should, however, be placed on the first page of each separate document, such as, a new application, amendment, assignment, and transmittal letter for a fee, along with the certificate of mailing by "Express Mail." Although the label number may be on checks, such a practice is not required.

In order not to deface formal drawings it is suggested that the label number be placed on the back of each formal drawing or the drawing be accompanied by a set of informal drawings on which the label number is placed

(Express Mail Certificate [8-3])

EJ4053.807.09US

Use of Acetylcholinesterase Inhibitors on the Modulation of the Hypothalamic-Pituitary-Gonadal Axis

Field of the Invention

The present invention relates to the use of centrally-acting cholinesterase inhibitors to modulate the hypothalamic-pituitary-gonadal axis by stimulating the secretion of gonadotropin releasing hormone. Such modulation finds use in, for example, stimulation of ovulation, in treatment of luteal phase defect, aesthenozoospermia and oligozoospermia, hypogonadotrophic hypogonadism, and in induction of puberty.

Background of the Invention

The purpose of this invention is to influence the secretion of gonadotropin releasing hormone (GnRH - may be known as GRF, previously referred to as LHRH or LRF) using orally-active preparations influencing central cholinergic activity.

The addition of acetylcholine to anterior pituitary glands incubated with hypothalamic fragments results in luteinizing hormone (LH) release, which can be blocked by muscarinic blockade by atropine. Prostigmine, an acetylcholinesterase inhibitor, as well as acetylcholine, enhance LH release in this system. (Fiorindo RP and Martini L, Evidence for a cholinergic component in the neuroendocrine control of luteinizing hormone secretion. Neuroendocrinology 18:322-332, 1975). Follicle stimulating hormone (FSH) levels are increased by the addition of hypothalamic fragments to incubated anterior pituitary glands, with a further increase produced by acetylcholine, an effect antagonized by atropine. (Simonovic J, Motta M and Martini L, Acetylcholine and the release of follicle stimulating hormone releasing factor. Endocrinology 95:1371, 1974). As cholinergic agents have no direct effect on anterior pituitaries to stimulate LH or FSH release, they were presumed to release gonadotropin-releasing hormone (GnRH, formerly thought to be two hormones, luteinizing hormone releasing hormone, LHRH, and follicle stimulating hormone releasing hormone, FSHRH) from the hypothalamus. Since the advent of assays for GnRH, this fact has been directly demonstrated. (Richardson SB, Prasad JA, Hollander CS, Acetylcholine, melatonin, and potassium depolarization stimulate release of luteinizing hormone-releasing hormone from rat hypothalamus in vitro. Proc Natl Acad Sci U S A 79(8):2686-9, 1982). In intact rats, injection of acetylcholine into the lateral ventricle stimulates LH release. This can be blocked with atropine or enhanced with prostigmine. Thus, cholinergic stimulation appears to cause GnRH release from the hypothalamus, apparently by a muscarinic mechanism.

Both muscarinic cholinergic blockade with atropine and nicotinic cholinergic stimulation appear to suppress gonadotropin release via hypothalamic mechanisms. Hemicastration in the female rat normally results in gonadotropin-mediated hypertrophy of

50441013 121408
80727 276709

the remaining ovary. This can be blocked by atropine implants into the anterior hypothalamus. (Monti JM, Sala MA, Otegui JE et al, Inhibition of ovarian compensatory hypertrophy by implants of atropine in the hypothalamus. *Experientia* 26:1263-1264, 1970) Similar implants blocked the post-orchidectomy rise in LH and FSH in male rats. No effect was seen of atropine implants into the pituitary, a finding consistent with the inability of acetylcholine to stimulate gonadotropin release from pituitary glands in vitro, as noted above. (Libertun C and McCann SM, Blockade of the postorchidectomy increase in gonadotropin by implants of atropine into the hypothalamus, *Proc Soc Exp Biol Med* 152:143-146, 1976) These data are consistent with the existence of a muscarinic cholinergic mechanism mediating GnRH release in the hypothalamus.

Conversely, nicotine administration suppresses LH secretion with consequent delay or inhibition of ovulation. (Blake CA, Parallelism and divergence in luteinizing and follicle stimulating hormone release in nicotine-treated rats. *Proc Soc Exp Biol Med* 145:716-720, 1974; Kanematsu S and Sawyer CH, Inhibition of the progesterone-advanced LH surge at proestrus. *Proc Soc Exp Biol Med* 143:1183-5, 1973; Blake CA, Scaramuzzi RJ, Norman RL, Kanematsu S and Sawyer CH, Nicotine delays the ovulatory surge of luteinizing hormone in the rat. *Proc Soc Exp Biol Med* 141:1014-1016, 1972) This action occurs within the hypothalamus, as complete surgical isolation does not alter it (Blake CA, Norman RL and Sawyer CH, Localization of the inhibitory actions of estrogen and nicotine on release of luteinizing hormone in rats. *Neuroendocrinology* 16:22-35, 1974) and it is not exerted at the pituitary, which is still fully responsive to exogenous LHRH. (Blake CA, Norman RL and Sawyer CH, Effects of hypothalamic deafferentation and ovarian steroids on pituitary responsiveness to LH-RH in female rats. In Gual and Rosemberg, eds, *Hypothalamic hypophysiotropic hormones*. Excerpta Medica, Amsterdam, 1973, pp. 33-38) Although nicotinic effects alone are inhibitory, the data indicate that the net effect of acetylcholinesterase inhibition or acetylcholine administration is to stimulate gonadotropin secretion.

Summary of the Invention

The present invention provides a method of treatment of conditions that can benefit from stimulation of the hypothalamic-pituitary-gonadal axis such as failure of ovulation, some cases of unexplained infertility, luteal phase defect, hypogonadotrophic hypogonadism, aesthenozoospermia and oligozoospermia and delayed onset of puberty.

Detailed Description of the Invention

Suitable acetylcholinesterase inhibitors for the present invention include those that have a central effect and have a medium to long duration of action (typically from 1.5 to 72 hours). Suitable acetylcholinesterase inhibitors are those that will pass easily through the blood-brain barrier. Suitable compounds for this purpose include donepezil, rivastigmine, galantamine, lycoramine and the analogs of galantamine and lycoramine wherein the methoxy group is replaced by another alkoxy group of from one to six carbon atoms, a hydroxy group, hydrogen, an alkanoyloxy group, a benzoyloxy or substituted benzoyloxy

group, a carbonate group or a carbamate group; wherein the hydroxy group is replaced by an alkoxy group of from one to six carbon atoms, hydrogen, an alkanoyloxy group, a benzoyloxy or substituted benzoyloxy group, a carbonate group or a carbamate group; and the N-methyl group by hydrogen, alkyl, benzyl or a cyclopropylmethyl group. Suitable analogs are described for example in International Patent Publication WO88/08708 and an article by Bores and Kosley in *Drugs of the Future* 21: 621-631 (1996).

GnRH and various longer acting agonists are used in a wide variety of clinical situations. They may be used to stimulate or suppress the HPG axis. They may be used alone, or in combination with gonadotropic preparations, hormones, or hormone antagonists. Short-term (or pulsatile) administration of GnRH stimulates gonadotropin secretion, while continuous administration or the use of long acting analogs for more than approximately two weeks desensitizes the gonadotropes and decreases gonadotropin secretion. This "medical castration" has numerous applications. (Ascoli M and Segaloff DL, *Adenohypophyseal hormones and their hypothalamic releasing factors*, in Goodman and Gilman's *The Pharmacological Basis of Therapeutics*, 9th edition, McGraw-Hill, New York, 1996, pp 1363-1382)

The peptides used to influence the reproductive axis must be given by injection, infusion or intranasally. LH and FSH preparations, including HCG and HMG, are given by injection. The subject of the present invention is the use of moderate or long-acting, orally available, centrally active cholinergic agents to stimulate gonadotropin secretion, alone or in combination with gonadotropins, GnRH, GnRH analogs or other hormonal preparations. Oral cholinergic agents may, in suitable patients, substitute for parenteral medications such as testosterone preparations or gonadotropins. The use of these agents could avoid the need for injections, subcutaneous or intravenous infusion pumps, and the inconvenience and risk of infection. Manipulation of the HPG axis for ovulation induction at the level of the hypothalamus is more physiological than GnRH and gonadotropins. It may be expected to reduce the incidence of ovarian hyperstimulation syndrome and multiple gestations, because normal feedback inhibitory mechanisms can operate at the level of the pituitary gland and the hypothalamus, just as the use of GnRH, acting on the pituitary gland, decreased the incidence of these complications from gonadotropin therapy, which acts directly on the ovaries. (Blacker CM, *Ovulation stimulation and induction*. *Endo Metab Clin N Am* 21(1):57-83, 1992)

The preferred agents for use in the present invention are rivastigmine and galantamine. Donepezil may be used in certain situations. These are acetylcholinesterase inhibitors which are well absorbed orally and partition preferentially to brain.

Rivastigmine has a plasma half life of 1-2 hours and is administered in doses of 0.5 to 10 mg two to six times a day, with a maximum daily dose of 18 mg. (Product Monograph: Exelon, Novartis Pharma AG, Basel, Switzerland, April 1998) Galantamine has a plasma half-life of 5 hours and is administered in doses of 1-20 mg two to four times a day with a maximum dose of 60 mg a day. (Westra P, et al *Pharmacokinetics of galantamine (a long-acting anticholinesterase drug) in anesthetized patients*. *Br J Anaesth* 58:1303-1307, 1986;

Mihailova D, et al Pharmacokinetics of galantamine hydrobromide after single subcutaneous and oral dosage in humans. *Pharmacology* 39:50-58, 1989). Donepezil is given in doses of 1-15 mg once daily. (Rogers SL, et al A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. *Neurology* 50:136-145, 1998) Doses for children may be proportionately reduced, and controlled-release dosage forms may override multiple dose schedules.

Common side effects include nausea and vomiting, anorexia, dizziness, fatigue, aesthenia. They are lessened by slow buildup of dose, and decrease with continued administration. Their frequency increases as the half-life of the compound decreases. Donepezil produces a higher frequency of muscle cramps than the shorter acting drugs, and insomnia, which they do not produce.

Cholinergic agents may exacerbate depression. Cholinergic agents exert vagotonic effects on the heart, and thus may exacerbate the sick sinus syndrome or bradycardia and may cause bronchoconstriction, particularly in patients with asthma and chronic obstructive pulmonary disease, may increase gastrointestinal motility or acid secretion, may theoretically increase bladder motility, may cause seizures or worsen Parkinsonian symptoms, or the symptoms of organophosphate anticholinesterase poisoning. There are insufficient data on the teratogenicity to rule out possible fetal malformations, and data on the safe use of these compounds in children are needed as well.

Ovulation-Inducing Protocols

Many patients with hypogonadotropic amenorrhea or hypothalamic dysfunction who are properly evaluated and followed and are deemed candidates for infusion pump treatment with GnRH may respond to the oral administration of acetylcholinesterase inhibitors. Protocols vary considerably among centers with the use of stimulatory agents guided by rises in plasma hormone measurements and ultrasound determinations of ovarian follicle size. The evaluation and monitoring used for GnRH administration would be used with acetylcholinesterase inhibitor ovulation induction. In the protocol employed by Blacker, for example, (Blacker CM, Ovulation stimulation and induction, *Endo Metab Clin N Am* 21(1):57-83, 1992) therapy is begun at the beginning of the follicular phase with the intermediate-acting agents, galantamine at 2-5 mg tid or rivastigmine at 1-2 mg tid, or appropriate delayed-release dosage form of either compound. If a normal follicular response as determined by transvaginal ultrasound or serum estradiol levels is not obtained, the dose may be increased to a maximum of galantamine, 15-20 mg tid, or rivastigmine, 4-6 mg tid, as tolerated. If the response is excessive at any point, dosages must be reduced to prevent ovarian hyperstimulation or multiple gestation. In unusual cases, the doses may be increased to galantamine, 30-35 mg tid, or rivastigmine, 8 mg tid. The small decrease in plasma hormone levels immediately preceding ovulation may be reproduced by decreasing or withholding medication for a short period. Luteal support may be provided by continuing the galantamine or rivastigmine for approximately two weeks, preferably at lower doses. Alternatively, luteal support may be provided, as in Blacker's description, with GnRH

infusion, HCG injections, or progesterone administration. Determination of a suitable dose may be accomplished by means known to those skilled in the art. It is, however, likely that the dose will vary between individuals and that it will only be established after several menstrual cycles.

Additional GnRH protocols have been described by Miller MM, Hoffman DI, Ovulation induction, in KL Becker, ed, Principles and Practice of Endocrinology and Metabolism JB Lippincott, Philadelphia, 1995, pp 900-909; Ascoli M and Segaloff DL, Adenohypophyseal hormones and their hypothalamic releasing factors, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition, McGraw-Hill, New York, 1996, pp 1363-1382; Fauser and Van Heusden, Endo Rev 18(1):71-106, 1997.

Superovulation in the Treatment of Unexplained Infertility

Cholinergic agents stimulate gonadotropin secretion in short-term studies of experimental animals and are of use in promoting the development of additional follicles during normal menstrual cycles in infertility cases. Studies with clomiphene or HMG injection suggest an increase in observed pregnancy rates. (Deaton JL, Gibson M, Nakajima ST et al, A randomized controlled trial of clomiphene citrate and intrauterine insemination versus well-timed intercourse in couples with unexplained infertility or surgically corrected endometriosis, Fertil Steril 54:1083, 1990; Collins JA, Superovulation in the treatment of unexplained infertility. Semin Reprod Endocrinol 8:165, 1990) A protocol similar to ovulation induction may be followed, with treatment continuing into the luteal phase if required due to luteal phase insufficiency, or standard luteal phase therapies may be used.

Luteal Phase Defect

Luteal phase dysfunction may be treated by acetylcholinesterase inhibitors of the present invention, using endometrial biopsies and serum progesterone concentrations to assess outcome. Treatment is begun at 2-5 mg galantamine-bid or tid, or 1-2 mg rivastigmine tid, and increased every few days in small increments until the desired result is obtained. It will take several cycles to establish the correct dose. Correction of the luteal phase dysfunction may require initiating treatment during the follicular phase. (Rebar RW, Disorders of menstruation, ovulation and sexual response, in KL Becker, ed, Principles and Practice of Endocrinology and Metabolism, JB Lippincott, Philadelphia, 1995, pp 880-899)

Hypogonadotropic Hypogonadism

Cholinesterase inhibitors of the present invention are of use for the stimulation of endogenous GnRH in patients who are potentially responsive such as women with functional hypothalamic amenorrhea, male acquired idiopathic hypogonadotropic hypogonadism, some cases of Kallman's syndrome or other hypothalamic dysfunction who may not have complete absence of GnRH cells. Initial doses of 2-5 mg of galantamine bid or tid or 1-2mg of

SECRET

rivastigmine could be raised by 4 mg of galantamine per day once a week, or 1-2 mg of rivastigmine once a day per week to a daily dose of 15-75 mg of galantamine or 8-18 mg of rivastigmine, with the final dose taken not later than late afternoon, to avoid continuous stimulation and subsequent downregulation. Alternatively, donepezil beginning at 5 mg/day, increasing to 10 mg/day after four weeks may be administered. Some patients may tolerate up to 15 mg/day. The lowest effective doses should be used.

The outcome measurements could, depending on the clinical objective and gender, include FSH or LH measurements, menstrual function, estradiol, progesterone or testosterone measurements, or sperm counts. Gonadotropin secretion should be monitored at intervals to ensure that stimulation has not been superseded by suppression after long-term treatment.


Induction of Puberty

The treatment protocol is essentially the same as for hypogonadotropic hypogonadism. Patients whose gonads and pituitary glands are responsive to GnRH, after priming, may have hypothalamic function sufficient to respond to cholinergic therapy. Given that the expected treatment with GnRH would involve several years of use of a portable infusion pump, a trial of oral cholinergic therapy may be reasonable to assess its potential. Using dosing regimens described above for hypogonadotropic hypogonadism, and allowing for a two-month period to comfortably reach an optimal dose with minimal induction of side effects, followed by four months of therapy, a six-month trial would be recommended to assess the potential for efficacy in an individual patient. The optimal dose will be individualized as with GnRH. Outcome measures may include hormone or gonadotropin measurements, testicular volume, growth velocity and development of secondary sexual characteristics. Gonadotropin secretion should be monitored at intervals to ensure that stimulation has not been superseded by suppression after long-term treatment.

Oligozoospermia and/or Aesthenozoospermia

Infertile males with normal or abnormal gonadotropins and low sperm counts or abnormal sperm characteristics have been treated with GnRH preparations with improvements. (Aulitzky W, Frick J, Hadziselimovic F, Pulsatile LHRH therapy in patients with oligozoospermia and disturbed LH pulsatility. *Int J Androl* 12(4):265-72, 1989; Matsumiya K, Kitamura M, Kishikawa H, Kondoh N, Fujiwara Y, Okuyama A, A prospective comparative trial of a gonadotropin-releasing hormone analogue with clomiphene citrate for the treatment of oligoaesthenozoospermia. *Int J Urol* 5(4):361-3, 1998) The same treatment regimen as proposed for hypogonadotropic hypogonadism is used here. A minimum of three months therapy is necessary to evaluate effects on sperm.

United States Patent & Trademark Office
Office of Initial Patent Examination – Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) _____ of No DECLARATION were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Scanned copy is best available.